6-氯甲基烟酸 | 148258-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯甲基烟酸
• 英文名称: 6-chloromethylnicotinic acid
• 英文别名: 6-(Chloromethyl)nicotinic acid；6-(chloromethyl)pyridine-3-carboxylic acid
• CAS: 148258-27-9
• 化学式: C₇H₆ClNO₂
• 分子量: 171.583
• InChiKey: QAUDCWDYPSYFFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-氯甲基烟酸 在 sodium hydroxide 、 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 38.25h， 生成 6-[[4-[3-(2H-tetrazol-5-yl)propoxy]phenoxy]methyl]pyridine-3-carboxylic acid
  参考文献：
  名称：

  Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships

  摘要：

  This series of reports describes the development of orally active, highly potent, specific antagonists of the peptidoleukotrienes containing a (2-quinolinylmethoxy)phenyl moiety. Described in this first report are the structure-activity relationships that led to a more than a 20-fold improvement of the potency and selectivity of the initial chemical lead (RG 5901). From this series of compounds, RG 7152 (16) was identified and selected for further evaluation in the clinic as an antiasthmatic agent. Compound 16 competitively inhibits [3H]LTD4 binding to membranes from guinea pig lung (Ki = 38 +/- 6 nM) and the spasmogenic activity of LTC4, LTD4, and LTE4 in parenchymal lung strips from guinea pigs. Unlike the original lead (RG 5901), compound 16 does not inhibit 5-lipoxygenase from guinea pig PMNs. Following oral administration to guinea pigs, 16 blocks LTD4-induced dermal permeability (ED50 = 6.9 mg/kg), LTD4-induced bronchoconstriction (ED50 = 1.1 mg/kg), antigen-induced bronchoconstriction (ED50 = 2.5 mg/kg), and anaphylactic-induced mortality (ED50 = 16 mg/kg). These studies on structure-activity relationships indicate that there is a requirement for an acidic function and the presence of the (2-quinolinylmethoxy)phenyl moiety in a specific geometric arrangement.

  DOI：

  10.1021/jm00166a016
• 作为产物：
  描述：

  2-氯甲基吡啶-5-羧酸甲酯 以 盐酸 为溶剂， 生成 6-氯甲基烟酸
  参考文献：
  名称：

  Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof

  摘要：

  本发明涉及被代换的烟酰胺和其类似物，由化学式V:1或其药学上可接受的盐或前药所代表，其中：Ar′和Ar分别是可选择代替的芳基或可选择代替的杂芳基，前提是所述可选择代替的杂芳基的环结构不超过两个氮原子；以及R11为氢；或烷基，环烷基，芳基或杂芳基，每种都可选择代替。本发明还涉及发现具有化学式V的化合物是caspases的激活剂和凋亡诱导剂。因此，本发明的化合物可用于诱导在各种临床病况中发生未受控制的异常细胞生长和扩散的细胞死亡。

  公开号：

  US20020010185A1

文献信息

• [EN] COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU CANCER ET ÉPIGÉNÉTIQUE
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2018151678A1

  公开（公告）日：2018-08-23

  The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereof, wherein the compound is useful for treating SMYD3- related cancer.

  本发明涉及具有通用公式（I）的杂环化合物，其中W1、W2、W3、W4、W7、W8、R1、R2、R3、R4、X2、X3、X4、Z1、Z2、Z3、Q、n和m如本文所述，或其药用可接受盐，其中该化合物用于治疗与SMYD3相关癌症。
• Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cytovia, Inc.

  公开号：US20020010185A1

  公开（公告）日：2002-01-24

  The present invention is directed to substituted nicotinamides and analogs thereof, represented by Formula V: 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein: Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and R 11 is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted. The present invention also relates to the discovery that compounds having Formula V are activators of caspases and inducers of apoptosis. Therefore, the compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及被代换的烟酰胺和其类似物，由化学式V:1或其药学上可接受的盐或前药所代表，其中：Ar′和Ar分别是可选择代替的芳基或可选择代替的杂芳基，前提是所述可选择代替的杂芳基的环结构不超过两个氮原子；以及R11为氢；或烷基，环烷基，芳基或杂芳基，每种都可选择代替。本发明还涉及发现具有化学式V的化合物是caspases的激活剂和凋亡诱导剂。因此，本发明的化合物可用于诱导在各种临床病况中发生未受控制的异常细胞生长和扩散的细胞死亡。
• [EN] SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF<br/>[FR] NICOTINAMIDES SUBSTITUEES, LEURS ANALOGUES, ACTIVATEURS DES CASPASES ET INDUCTEURS DE L'APOPTOSE ET LEUR EMPLOI
  申请人：CYTOVIA INC

  公开号：WO2001055115A1

  公开（公告）日：2001-08-02

  The present invention is directed to substituted nicotinamides and analogs thereof, represented by Formula (V) or a pharmaceutically acceptable salt or prodrug thereof, wherein: Ar' and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and R11 is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted. The present invention also relates to the discovery that compounds having Formula (V) are activators of caspases and inducers of apoptosis. Therefore, the compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及代替烟酰胺和其类似物，由式（V）或其药学上可接受的盐或前药所表示，其中：Ar'和Ar分别是可选取的取代芳基或可选取的取代杂环芳基，但所述可选取的杂环芳基的环结构不包括超过两个氮原子；R11是氢；或是可选取的烷基、环烷基、芳基或杂环芳基，每个都可以被取代。本发明还涉及到发现具有式（V）的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的化合物可用于在各种临床情况下诱导细胞死亡，其中发生异常细胞的无控制生长和扩散。
• Thiazole derivatives
  申请人：Nakajima Takao

  公开号：US20070105919A1

  公开（公告）日：2007-05-10

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n为0至3的整数；R1代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2代表卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8或类似物；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基烷基、-COR12或类似物。例如，提供了包含噻唑衍生物的腺苷A2A受体拮抗剂作为活性成分，其表示为通式（I）或其药学上可接受的盐等。
• THIAZOLE DERIVATIVES
  申请人：Nakajima Takao

  公开号：US20110105486A1

  公开（公告）日：2011-05-05

  Wherein n is an integer of from 0 to 3; R 1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R 2A is —COR 8 (wherein R 8 is aryl); R 3A is hydrogen or lower alkyl; and R 12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R 1A , R 2A , R 3A and R 12 are individually optionally substituted.

  其中n是0到3的整数；R1A是一个含有至少一个氧原子的5-成员芳香杂环基团；R2A是-COR8（其中R8是芳香基）；R3A是氢或较低的烷基；而R12代表环烷基，芳香基，芳基烷基，脂环杂环基团，芳香杂环基团，脂环杂环烷基或芳香杂环烷基，R1A，R2A，R3A和R12都可以个别地选择性地被取代。